Literature DB >> 35709756

Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment.

Hee-Jin Jang1, Hyun-Sung Lee1, Bryan M Burt1, Wendong Yu2, Maheshwari Ramineni3, Cynthia Y Truong1, Daniela Ramos1, Taylor Splawn1, Jong Min Choi1, Sung Yun Jung4, Ju-Seog Lee5, Daniel Y Wang6, Joel M Sederstrom7, Massimo Pietropaolo8, Farrah Kheradmand9,10, Christopher I Amos, Thomas M Wheeler, R Taylor Ripley.   

Abstract

SIGNIFICANCE: Comprehensive single-cell proteomics analyses of lung adenocarcinoma progression reveal the role of tumor-associated macrophages in resistance to PD-1 blockade therapy. See related commentary by Lee et al., p. 2515. ©2022 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2022        PMID： 35709756      PMCID： PMC9296613          DOI： 10.1158/0008-5472.CAN-21-3506

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   13.312


  61 in total

1.  Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages.

Authors:  Don-Hong Wang; Hyun-Sung Lee; David Yoon; Gerald Berry; Thomas M Wheeler; David J Sugarbaker; Farrah Kheradmand; Edgar Engleman; Bryan M Burt
Journal:  Clin Cancer Res       Date:  2016-08-05       Impact factor: 12.531

2.  Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry.

Authors:  Charlotte Giesen; Hao A O Wang; Denis Schapiro; Nevena Zivanovic; Andrea Jacobs; Bodo Hattendorf; Peter J Schüffler; Daniel Grolimund; Joachim M Buhmann; Simone Brandt; Zsuzsanna Varga; Peter J Wild; Detlef Günther; Bernd Bodenmiller
Journal:  Nat Methods       Date:  2014-03-02       Impact factor: 28.547

3.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

Review 4.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

5.  Dendritic cells recruited to the lung shortly after intranasal delivery of Mycobacterium bovis BCG drive the primary immune response towards a type 1 cytokine production.

Authors:  Micheline Lagranderie; Marie-Anne Nahori; Anne-Marie Balazuc; Hélène Kiefer-Biasizzo; Jose-Roberto Lapa e Silva; Geneviève Milon; Gilles Marchal; Boris B Vargaftig
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

6.  Identification of mRNAs and lincRNAs associated with lung cancer progression using next-generation RNA sequencing from laser micro-dissected archival FFPE tissue specimens.

Authors:  Rom S Leidner; Cheryl L Thompson; Matthew L Morton; Xiaodong Bai; Callie R Merry; Philip A Linden; Ahmad M Khalil
Journal:  Lung Cancer       Date:  2014-03-29       Impact factor: 5.705

7.  EpEX/EpCAM and Oct4 or Klf4 alone are sufficient to generate induced pluripotent stem cells through STAT3 and HIF2α.

Authors:  I-I Kuan; Kang-Hao Liang; Yi-Ping Wang; Ting-Wen Kuo; Yaa-Jyuhn James Meir; Sareina Chiung-Yuan Wu; Shang-Chih Yang; Jean Lu; Han-Chung Wu
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

8.  Automated cell segmentation in FIJI® using the DRAQ5 nuclear dye.

Authors:  Mischa Schwendy; Ronald E Unger; Mischa Bonn; Sapun H Parekh
Journal:  BMC Bioinformatics       Date:  2019-01-18       Impact factor: 3.169

9.  Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma.

Authors:  Heike Zabeck; Hendrik Dienemann; Hans Hoffmann; Joachim Pfannschmidt; Arne Warth; Philipp A Schnabel; Thomas Muley; Michael Meister; Holger Sültmann; Holger Fröhlich; Ruprecht Kuner; Felix Lasitschka
Journal:  PLoS One       Date:  2018-10-23       Impact factor: 3.240

Review 10.  Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Huizhen Suo; Reni Kitte; Sarah Dluczek; Alexander Strauß; André-René Blaudszun; Tetyana Yevsa; Stephan Fricke; Uta Kossatz-Boehlert
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.